Precision Antibody-Based Therapeutics

We are experts in antibody-drug conjugate development, translational medicine, clinical advancement, and biotech venture creation. Our deep scientific expertise and track record in launching new therapies empower us to push the boundaries of cancer treatment.

We develop monoclonal antibody-based therapies targeting novel, tumor-specific cell surface proteins. By leveraging the unique biology of these proteins, we are creating safer, more effective cancer treatments for patients who need new options most.

Patients with aggressive cancers too often face poor outcomes and limited choices. Our mission is to revolutionize cancer prognosis by focusing on indications where antibody-based breakthroughs have yet to make their mark—advancing precision oncology and delivering hope where it’s needed most.